Skip to main content
. Author manuscript; available in PMC: 2014 Nov 5.
Published in final edited form as: Minerva Endocrinol. 2013 Jun;38(2):145–163.

Figure 2.

Figure 2

Structure of slow acting (basal) insulin analogs. Glargine (FDA-approved; top panel) has a substitution of glycine at A21 and two arginines added to the carboxy terminal of the B chain. In contrast, Detemir (FDA-approved; middle panel) has a myristic acid bound to lysine at B29. The bottom panel depicts Degludec (not approved by the agency), which has the B30 residue deleted, has no amino acid substitutions, and has conjugated hexadecanedioic acid to the lysine at B29.